Advancing cancer detection through biology + AI.

Ajit Singh, Ph.D.

Chief Executive Officer

Ajit Singh was most recently at Artiman Ventures where he focused on early-stage technology and life science investments and represented the firm on the boards of Aditazz, CORE Diagnostics and OncoStem Diagnostics.

Dr. Singh is also an Adjunct Professor in the School of Medicine at Stanford University and serves on the Board of Trustees of the American Association for Cancer Research (AACR).

Prior to joining Artiman, Dr. Singh was the President and CEO of BioImagene (acquired by Roche), a Digital Pathology company. Before BioImagene, he spent nearly twenty years at Siemens in various roles, most recently as the Chief Executive Officer of the Digital Radiology and Medical Informatics business of Siemens Healthcare. His previous roles included President and CEO of the Oncology Care Systems Group, Group Vice President of Siemens e-Health, and Vice President of Siemens Health Services. From 1989 to 1995, he was at Siemens Corporate Research working on Artificial Intelligence, Robotics, Computer Vision, and Image Analysis. During this time, he concurrently served on the faculty at Princeton University.

Dr. Singh has a Ph.D. in Computer Science from Columbia University, a master’s degree in Computer Engineering from Syracuse University, and a bachelor’s degree in Electrical Engineering from Banaras Hindu University, India. He has published two books and numerous refereed articles and holds five patents.

Hutan Ashrafian, M.D., Ph.D., M.B.A.

Chief Medical Officer

Hutan Ashrafian, M.D., Ph.D, M.B.A. is Chief Medical Officer at Harbinger Health and Chief Scientific Officer of Flagship Pioneering’s Preemptive Medicine and Health Security Initiative.

Hutan is a senior clinician-scientist and surgeon with extensive experience developing novel biomedical and technological methods to address a wide range of healthcare issues. His research has focused on developing innovative and technological strategies to resolve the global healthcare burden of obesity, metabolic syndrome, obesity-related cardiorespiratory disease, musculoskeletal dysfunction, and cancer. He has extensive experience applying AI to medicine. He developed an algorithm with Google to detect breast cancer in screening images and led the translation of this work into clinical practice. He also spearheaded the international STARD-AI and QUADAS-AI global reporting guideline initiatives for diagnostic AI. In collaboration with NICE, he is setting the AI health technology assessment (HTA) benchmarks, and he is co-editor-in-chief of Springer Nature’s comprehensive reference text of AI in Medicine.

Hutan has held multiple scientific and clinical positions including: Chief Scientific Adviser at the Institute of Global Health Innovation, Imperial College London; Honorary Senior Clinical Fellow in Surgery at Imperial College Healthcare NHS Trust; Academic Lead for the Big Data Analytical Unit, Imperial College London; Deputy Director (Academic Lead) for the NHS Digital Academy; Co-Founder and Chief Medical Officer at Oxford Medical Products Ltd. His wide-ranging work has been published in a variety of leading journals including Nature, The Lancet and The New England Journal of Medicine.

Hutan earned his degree in Medicine at University College London where he also received an honors degree in Immunology and Cell Pathology. He holds a Ph.D. in Computational Physiology and Metabolic Surgery from Imperial College London and a health economics-focused M.B.A. with Distinction from Warwick Business School.

Tony Shuber

Chief Innovation Officer

Anthony (Tony) Shuber serves as Chief Innovation Officer at Harbinger Health. He is a scientific leader in the life sciences industry with over 25 years of experience in Diagnostics and Applied Genomics, and is the co-founder of several companies, including EXACT Science Corporation and Predictive Biosciences. Tony was most recently President and CTO of Genetics Research, LLC and Stitch Bio.

A prolific inventor, visionary and problem solver, Tony is the holder of over 100 issued and pending patents and has numerous publications in such prestigious journals as The New England Journal of Medicine. He is the inventor behind well-known innovations in molecular diagnostics that are standard of practice tests today including ColoGuard, a test for early identification of colorectal cancer. Tony also holds advisory and Board of Director positions and is well known in the venture capital community. He earned his undergraduate (BS in Biology) and graduate (MS in Molecular and Developmental Biology) degrees from Marquette University, Milwaukee, Wisconsin.

Prof. Franziska Michor, Ph.D.

Chief Scientific Advisor & Co-Founder

Franziska Michor, Ph.D. serves as the Chief Scientific Advisor at Harbinger Health and is a Professor of Computational Biology in the Department of Data Science at the Dana-Farber Cancer Institute, in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health, and in the Department of Stem Cell and Regenerative Biology at Harvard University.

Dr. Michor obtained her undergraduate training in mathematics and molecular biology from the University of Vienna, Austria, and her PhD from the Department of Organismic and Evolutionary Biology at Harvard University. Afterwards, she was awarded a fellowship from the Harvard Society of Fellows. From 2007 until 2010, she was an Assistant Professor in the Computational Biology Program at Memorial Sloan-Kettering Cancer Center. Dr. Michor is the director of the Dana-Farber Cancer Institute Center for Cancer Evolution and co-directs the Cancer Immunological Data Commons. She has been the recipient of the Theodosius Dobzhansky Prize of the Society for the Study of Evolution, the Alice Hamilton Award, the Vilcek Prize for Creative Promise in Biomedical Science, the 36th Annual AACR Award for Outstanding Achievement in Cancer Research, and others.

Dr. Michor’s laboratory investigates the evolutionary dynamics of cancer initiation, progression, response to therapy, and emergence of resistance.

Avni B. Santani, Ph.D., FACMG

SVP, Head of Platform

As SVP, Head of Platform at Harbinger Health, Avni leads Data Science, Clinical Laboratory Operations, and Research & Development. She brings over two decades of experience at the intersection of genomics, molecular diagnostics, and precision medicine — with a track record of building and scaling clinical testing programs that translate scientific discovery into actionable patient care.

Prior to Harbinger, Dr. Santani served as Chief Genomics Officer at LetsGetChecked and Chief Medical Officer at Veritas Genetics, and founded Opus Genomics, a rare disease company. She spent more than a decade at The Children’s Hospital of Philadelphia, where she served as Director of the Division of Genomic Diagnostics and Director of CLIA Laboratories within the Center for Applied Genomics, and held a faculty appointment at the Perelman School of Medicine at the University of Pennsylvania. She is also the Founder of Boston Health Partners and the host of On Target, a podcast exploring the future of diagnostics and precision healthcare.

A board-certified clinical molecular geneticist and cytogeneticist, Dr. Santani has published more than 60 peer-reviewed papers and has been an active leader in shaping national standards for next-generation sequencing — through the Association for Molecular Pathology, College of American Pathologists, and Clinical Laboratory Standards Institute. She is a recipient of the Philadelphia Business Journal’s Innovator of the Year Award and has been recognized among the Top 25 Women Leaders in Healthcare Technology.

Anli Serfontein, CPA

SVP, Head of Finance, HR & Legal

As SVP, Head of Finance, HR & Legal, Anli is a result-driven finance leader with more than 20 years of progressive experience in accounting, operations, and management. Her strong leadership, communications, and interpersonal skills have helped her establish rapport with all levels of staff and management to take on new challenges, utilizing her experience to improve processes, motivate others and deliver results.

Prior to joining Harbinger, Anli was the Senior Director, Head of US Finance for Zealand Pharma A/S a Danish-based biotechnology company focused on the discovery, design, and development of innovative peptide-based medicines. During her time at Zealand, she was responsible for leading the U.S. accounting and reporting team in their efforts to report into the consolidated financial statements while ensuring compliance with U.S. and Danish accounting standards.  Prior to Zealand, she worked as a Director at The Siegfried Group, a leading national CPA firm that provides leadership advisory and talent delivery services where she assisted companies in various life science, technology, and health care companies with financial assistance during critical times of need. Earlier in her career, she worked in public accounting as an Audit Manager for CBIZ & MHM New England, an Audit Manager for BKR Logista, and an Audit Associate for IAPA Johannesburg in South Africa.

Anli earned her Honors Bachelor of Accounting Science at UNISA and Bachelor of Science, Accounting at the University of Johannesburg in South Africa and is a registered CPA in the Commonwealth of Massachusetts.

Elie Massaad, M.D., M.Sc.

VP, Product & Clinical Strategy

Elie Massaad, M.D., M.Sc., is a physician-scientist focused on precision medicine and biomarker-guided drug development. He currently serves as VP, Product & Clinical Strategy, where he leads product strategy and clinical development for a pipeline of liquid biopsy applications in oncology.

Dr. Massaad brings experience across clinical development, regulatory strategy, and medical affairs, and is particularly focused on how emerging biomarker technologies can advance diagnostic and therapeutic development and extend their impact in clinical care. He has partnered across scientific, clinical, and product teams to help bring biomarker-driven approaches from early concept to practical application across multiple therapeutic areas, including oncology, autoimmune diseases, and related fields.

Prior to joining Harbinger, Dr. Massaad contributed to multidisciplinary efforts at Massachusetts General Hospital and Harvard Medical School to advance care for patients with primary and metastatic central nervous system tumors. He earned a Master of Science in Clinical Investigation from Harvard Medical School and a Doctor of Medicine from the American University of Beirut. Dr. Massaad has authored more than 100 publications and has received multiple awards from national professional societies, including the Congress of Neurological Surgeons.

Michele Andrasik, Ph.D.

Fred Hutchinson Cancer Research Center

Director, Social & Behavioral Sciences
Community Engagement
Operation Warp Speed

Sumithra Mandrekar, Ph.D.

Mayo Clinic
Lead faculty statistician for lung cancer research

John Mendlein, Ph.D.

Flagship Pioneering
Executive Partner

Scott Kopetz, M.D., Ph.D., FACP

MD Anderson Cancer Center
Professor, Department of Gastrointestinal Medical Oncology

Funda Meric-Bernstam, M.D.

MD Anderson Cancer Center
Chair Department of Investigational Cancer Therapeutics

Richard P. Shannon, M.D.

Duke University Health System
Chief Quality Officer
Board member, Kaiser Foundation

Robert A. Weinberg, Ph.D.

Massachusetts Institute of Technology
Daniel K. Ludwig Professor for Cancer Research

Matt Turner

Executive Advisor

Matt Turner is a growth-oriented senior business executive passionate about advancing human health and planetary well-being. With a career spanning life sciences, diagnostics, dental medical devices, and energy, Matt has built a reputation as a transformative leader who delivers market-leading performance with meaningful global impact. Across sectors, he has guided businesses at the intersection of science, innovation, and sustainability— driving breakthroughs that improve lives and create long-term value through top-line growth and sustainable margin expansion.

Matt is a purpose-driven leader who is deeply committed to developing high-performing, engaged global teams. His leadership style is marked by clarity of vision, relentless focus on outcomes, and a belief in unlocking potential through empowerment. He has consistently inspired organizations to pursue ambitious goals—and exceed them.

Matt’s leadership extends beyond business. Among other boards, he has served on the MIT Corporation (MIT’s board of trustees), where he chaired a committee and served on several departmental Visiting Committees. He also recently completed a five-year term on the MIT Alumni Association Board. An Eagle Scout, he serves as a leader for his local Boy Scout troop—reflecting his belief in values-based leadership and mentorship for the next generation.

A native of Amityville, NY, Matt earned dual Bachelor of Science degrees in Mechanical Engineering and Political Science from MIT, and an MBA from the Harvard Business School, where he graduated as a Dean’s Award recipient. He lives with his wife and three children in the Los Angeles metropolitan area.

Kieran Chacko, Ph.D.

Executive Advisor

A biotechnology entrepreneur and scientist, Kieran has co-founded multiple companies, including Harbinger Health and Ambrosia Biosciences. Before joining Harbinger, he was a Principal at Flagship Pioneering, a venture creation firm, where he collaborated with teams to create and scale transformative biotechnology companies, including Harbinger Health.
 
Kieran began his career at J.P. Morgan Chase & Co in New York City within the Corporate and Investment Bank, working across the markets and securities divisions to support the firm’s large corporate, financial institution, and emerging market clients.

He holds a Ph.D. in Computational Biology from the Icahn Institute for Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai in New York City, where he currently serves on the Alumni Advisory Council.

Prof. Alexander Meissner, Ph.D.

Scientific Advisory Board & Co-Founder

Dr. Meissner is Scientific Member of the Max Planck Society and currently the Managing Director of the Max Planck Institute for Molecular Genetics in Berlin. He is heading the Department of Genome Regulation and remains a Visiting Scholar in the Department of Stem Cell and Regenerative Biology at Harvard University. Before his move to the Max Planck Institute he was a tenured Professor at Harvard University and Senior Associate Member of the Broad Institute where he co-directed the Epigenomics Program.

Dr. Meissner obtained his undergraduate training in biotechnology from the Technical University in Berlin, Germany and completed is PhD and postdoctoral training at the Whitehead Institute (Massachusetts Institute of Technology) in Cambridge, USA. He is the recipient of a Weizmann Institute of Science, Karyn Kupcinet fellowship, a Boehringer Ingelheim PhD fellowship, a Pew Biomedical Scholarship and was named a New York Stem Cell Foundation, Robertson Investigator as well as elected as a Member to the European Molecular Biology Organization.

Dr. Meissner’s laboratory uses genomic tools to study developmental and disease biology with a particular focus on epigenetic regulation. Dr. Meissner and his colleagues have pioneered next generation sequencing technologies to study the epigenome in mammalian development and disease.

Prof. Zachary Smith, Ph.D

Scientific Advisory Board & Co-Founder

Dr. Smith is an Assistant Professor at the Yale Stem Cell Center, Department of Genetics, and Yale Cancer Center.

Dr. Smith received his B.S. in Biology from M.I.T. in 2008 and joined Dr. Alex Meissner’s new lab at Harvard University’s Department of Stem Cell and Regenerative Biology shortly thereafter. During his time there, Zack published research on direct reprogramming of somatic cells to pluripotency, including early cellular and epigenetic dynamics, and applied emerging genome-scale technologies to study DNA methylation in precious samples.  He continued applying cutting edge technologies to study the cellular and epigenetic dynamics that accompany critical windows of animal development from fertilization through the formation of the initial body plan.  Zack received his Ph.D. in 2019 and joined the Yale Stem Cell Center and Department of Genetics as an Assistant Professor in September, 2020.  He has been the recipient of the NIH Director’s New Innovator Award, the Chen Innovator Award, a Mathers Foundation Fellowship, and the Kingsley Fellowship.

Doug Cole, M.D.

Co-Founder & Managing Partner
Flagship Pioneering

Doug Cole joined Flagship Pioneering in 2001. He focuses on life science.

At Flagship, Doug has co-founded Ensemble Therapeutics, Foghorn Therapeutics(NASDAQ: FHTX), Inzen Therapeutics, Moderna(NASDAQ: MRNA), Permeon Biologics, Sigilon Therapeutics, (NASDAQ: SGTX), and Syros Pharmaceuticals (NASDAQ: SYRS). He has led investments in Agios Pharmaceuticals (NASDAQ: AGIO), Alvine Pharmaceuticals, Avedro(NASDAQ: AVDR, acquired by Glaukos), CombinatoRx (NASDAQ: ZLCS), Concert Pharmaceuticals (NASDAQ: CNCE), Denali Therapeutics (NASDAQ: DNLI), Editas(NASDAQ: EDIT), Quanterix Corporation(NASDAQ: QTRX), Receptos (NASDAQ: RCPT, acquired by Celgene), Seventh Sense Biosystems, Tetraphase Pharmaceuticals (NASDAQ: TTPH), and Torque.

He currently serves on the board of directors of Denali Therapeutics, Foghorn Therapeutics, KSQ Therapeutics, Harbinger Health, Inzen Therapeutics, Repertoire Immune Medicines, Sana Biotechnology (NASDAQ: SANA), and Sigilon Therapeutics. He formerly served on the board of directors of Avedro, AVEO Oncology (NASDAQ: AVEO), CombinatoRx, Concert Pharmaceuticals, CGI, Moderna, Morphotek (acquired by Eisai Pharmaceuticals), Receptos, Resolvyx, Selecta(NASDAQ: SELB), Seventh Sense, Taris (acquired by JNJ), and Tetraphase.

Before joining Flagship, Doug was instructor in neurology at Harvard Medical School and assistant in neurology at the Massachusetts General Hospital; medical director at Cytotherapeutics, in Providence, Rhode Island; and program executive at Vertex Pharmaceuticals, Inc., in Cambridge, Mass.
He holds an A.B. magna cum laude with high distinction in English from Dartmouth College, where he was a senior fellow and a member of Phi Beta Kappa, and an M.D. from the University of Pennsylvania School of Medicine, where he was a member of Alpha Omega Alpha. He obtained post-graduate training in medicine at the Johns Hopkins Hospital in Baltimore, and in neurology at the Massachusetts General Hospital in Boston, Mass.

Doug is a member of the scientific advisory board and the board of directors of the Spinal Muscular Atrophy Foundation.

Lord Ara Darzi, M.D.

Chairman, Pre-emptive Medicine & Health Security
Flagship Pioneering

The Right Honourable Professor the Lord Darzi of Denham OM KBE FRS holds the Paul Hamlyn Chair of Surgery at Imperial College London, the Royal Marsden Hospital and the Institute of Cancer Research. He is Director of the Institute of Global Health Innovation at Imperial College London and Chair of Imperial College Health Partners. Professor Darzi is an Honorary Consultant Surgeon at Imperial College Hospital NHS Trust.

Research led by Professor Darzi is directed towards achieving best surgical practice through innovation in surgery and enhancing patient safety and the quality of healthcare. His contribution within these research fields has been outstanding, publishing over 800 peer-reviewed research papers to date. In recognition of his achievements in the research and development of surgical technologies, Professor Darzi has been elected as an Honorary Fellow of the Royal Academy of Engineering; a Fellow of the Academy of Medical Sciences and in 2013 was elected as a Fellow of the Royal Society.

He was knighted for his services in medicine and surgery in 2002. In 2007, he was introduced to the United Kingdom’s House of Lords as Professor the Lord Darzi of Denham and appointed Parliamentary Under-Secretary of State at the Department of Health. Upon relinquishing this role within central government in 2009, Professor Darzi sat as the United Kingdom’s Global Ambassador for Health and Life Sciences until March 2013. During this appointment and beyond Professor Darzi has developed his status as a leading voice in the field of global health policy and innovation. Professor Darzi was appointed a member of Her Majesty’s Most Honourable Privy Council in June 2009 and in January 2016 he was introduced to the Order of Merit, the highest civilian honour in the United Kingdom, for exceptionally meritorious service towards the advancement of medicine.

Margo Georgiadis

Co-Founder & CEO, Montai Therapeutics
CEO-Partner, Flagship Pioneering

Margo Georgiadis is a CEO-Partner at Flagship Pioneering and Co-Founder and CEO of Montai Therapeutics. In these roles, Margo brings extensive expertise in technological innovation and high-performance business transformation and leverages her artificial intelligence and machine learning experience to advance biotech innovation. Working with Flagship CEO and Founder Noubar Afeyan and Lord Ara Darzi, she plays an instrumental role in Flagship’s efforts to scale its Preemptive Medicine & Health Initiative and develop new companies aimed at deterring or delaying the onset of disease, improve health outcomes for consumers, corporations, and countries.

Margo is an experienced CEO and company builder who has dedicated her career to transforming products and services with data and technology to empower consumers to live better lives, and to deliver outsized growth and returns for investors. Most recently, she served as an Endurance Partner at venture catalyst firm General Catalyst, where she focused on building next-generation healthcare platforms that improve clinical outcomes while making healthcare more consumer-centric, accessible and affordable. Previously, she served as President and CEO of Ancestry where she brought together content, science, and technology to transform Ancestry into the undisputed global leader in family history and consumer genomics. Under her leadership, the company scaled to over 3.6M subscribers, doubled its genomics network to over 20M customers and delivered over $1B in subscription revenue with record setting profitability and cash flow.

Margo also spent nine years at Google as President of Americas and Vice President of Global Operations, leading the hyper scaling of Google’s commercial operations and advertising sales across all digital solutions including search, mobile, video, shopping, local and commerce, and platforms. Her other operating roles include serving as the CEO of Mattel, Inc., the COO of Groupon, EVP of US Card Services and CMO at Discover Financial Services, and as a partner at McKinsey and Company.

Beyond her operating roles, Margo is an experienced investor at the intersection of health and technology and has helped to scale multiple successful platform companies as an Endurance Partner at General Catalyst and a Managing Partner at Synetro Group.

Margo has received multiple awards for her business and community leadership including the Forbes “Excellence Award in Innovation,” Chicago Innovation’s “Visionary Award,” the Eastman Medal from the University of Rochester, Executive of the Year in Utah, and was named to Crain’s “Most Powerful Women in Business” and Fortune’s “50 Most Powerful Women in Business” lists.

Margo serves on multiple Boards including McDonald’s, Applovin, Ro, Handshake, the Parker Institute for Cancer Immunotherapy and People’s Health Clinic. She earned a BA in Economics from Harvard College and an MBA from Harvard Business School.

Stephen Hahn, M.D.

CEO Emeritus & Special Advisor
Harbinger Health

Stephen M. Hahn, M.D., is CEO Emeritus and Special Advisor at Harbinger Health. Steve led Harbinger as CEO from 2021 to 2025.

Steve brings two decades of distinguished leadership in healthcare strategy, oncology medical practice, and translational/clinical research to this role. He served as the 24th U.S. Food and Drug Administration (FDA) Commissioner from 2019 to 2021 overseeing both COVID and non-COVID regulatory affairs, including therapeutics and vaccine development, devices, diagnostics, and clinical trials.

Prior to his FDA appointment, Steve served as chief medical executive at the world-renowned MD Anderson Cancer Center in Houston. Prior to his role as chief medical executive, he served as deputy president and chief operating officer where he was responsible for the day-to-day operations of the nation’s top cancer center, which included leading more than 21,000 employees and overseeing a $5.2 billion operating budget. Steve was elevated to the chief operating officer role after serving as division head, department chair, and professor of Radiation Oncology. Prior to his executive leadership roles at MD Anderson, Dr. Hahn was the leader of radiation oncology at the University of Pennsylvania’s Perelman School of Medicine.

Steve focused his translational research efforts on the evaluation of the tumor microenvironment, signal transduction pathways involved in tumor response to therapies and proton therapy. He has authored more than 220 peer-reviewed original research articles and has experience in medical product development.

Steve earned his M.D. from Temple University and received his B.A. in Biology from Rice University. He was an internal medicine resident at the University of California San Francisco before completing a fellowship and residency at the National Cancer Institute in Bethesda, Maryland.

Jeffrey Luber

Growth Partner, Flagship Pioneering

Jeffrey (Jeff) R. Luber joined Flagship Pioneering in 2026 and serves as a Growth Partner, where he supports efforts to maximize the value and impact of companies across the Flagship ecosystem.

Jeff is a four-time CEO and board member of public and private companies, known for scaling regulated healthcare and diagnostics companies at critical inflection points. An EY Entrepreneur of the Year (2022), Jeff has raised over $400M across his career and has repeatedly built and led teams that deliver regulatory success, commercial scale, and strategic exits.

He led EXACT Sciences (NASDAQ: EXAS) through early commercialization, securing American Cancer Society endorsement and a $24M non-dilutive capital infusion that preserved and strengthened the company’s market trajectory. He reset and scaled Good Start Genetics to a multi-million-dollar revenue run rate, expanded national reimbursement, and led the company through a successful exit. At binx health, Jeff rebuilt the business from R&D-stage to commercial company, leading to two FDA clearances and a CLIA waiver, multiple successful fundraising rounds, national distribution, global manufacturing, and a digital health spin-out, before transitioning to Chairman.

Most recently, Jeff led Clairity to the first FDA authorization for AI-driven breast cancer risk prediction and $43M in Series B financing, setting the stage for broad commercialization.

Jeff received his J.D., cum laude, and his MBA from Suffolk University.

Michael Nally, M.B.A.

CEO, Generate Biomedicines
CEO-Partner, Flagship Pioneering

Michael Nally joined Flagship in 2021 and serves as CEO-Partner and Chief Executive Officer of Generate Biomedicines. Mike is an accomplished pharmaceutical executive, with significant experience leading global organizations.

Prior to joining Flagship, Mike spent nearly 18 years at Merck, where he was most recently Executive Vice President and Chief Marketing Officer of its Human Health division. In this role, he led the company’s global marketing strategy, commercialization model, and long-term growth strategy across its product portfolio. Mike previously served as President of Merck’s Global Vaccines division where he and his team increased the reach and public health impact of its portfolio of pediatric, adolescent, and adult vaccines resulting in significant business growth. He also led Merck’s business in Sweden and the UK, and developed innovative, customer-centered approaches that improved business results and accelerated patient access to the company’s medicines and vaccines. Additionally, he held a variety of senior positions at Merck in commercial operations, business development, and investor relations.

Mike holds an M.B.A. from Harvard Business School, a degree in Accounting and Finance from the London School of Economics, and a B.A. in Economics from Middlebury College.

Stephen H. Rusckowski

Retired Chairman, CEO & President
Quest Diagnostics

Steve Rusckowski retired as Chairman of the Board of Quest Diagnostics on March 31, 2023.

He served as President and Chief Executive Officer of Quest Diagnostics from May 2012 through October 2022, and during that time focused on transforming the company, based on its compelling vision of “Empowering better health with diagnostic insights.” Under Steve’s leadership, the company refocused on its core diagnostic information services business, sold non- core assets, delivered disciplined deployment, including share repurchases and acquisitions, and simplified its organizational structure to better serve customers by removing complexity, speeding decision making and empowering employees. He was elected Chairman of the Board in December 2016.

Prior to joining Quest Diagnostics, Steve was CEO of Philips Healthcare, which became the largest unit of Royal Philips Electronics under his leadership. He joined Philips in 2001 when it acquired the Healthcare Solutions Group, he was leading at Hewlett-Packard/Agilent Technologies.

Steve was a member of the Board of Directors of the American Clinical Laboratory Association and served as its Chairman from 2014 to 2017. He is also an Emeritus Director of Project Hope, a global health education and humanitarian assistance organization.

He currently serves on the boards of Baxter International, Tenet, Qiagen and Harbinger Health.  Steve is also on the board of executives of MIT’s Sloan School of Management, Vice Chairman of Board of Trustees of Worcester Polytechnic Institute and board member of the Focused Ultrasound Foundation.

Steve earned a Master of Science degree in Management from the Massachusetts Institute of Technology’s Sloan School of Management and a Bachelor of Science degree in Mechanical Engineering from Worcester Polytechnic Institute.

Ajit Singh, Ph.D

CEO, Harbinger Health
CEO-Partner, Flagship Pioneering

Ajit Singh was most recently at Artiman Ventures where he focused on early-stage technology and life science investments and represented the firm on the boards of Aditazz, CORE Diagnostics and OncoStem Diagnostics.

Dr. Singh is also an Adjunct Professor in the School of Medicine at Stanford University and serves on the Board of Trustees of the American Association for Cancer Research (AACR).

Prior to joining Artiman, Dr. Singh was the President and CEO of BioImagene (acquired by Roche), a Digital Pathology company. Before BioImagene, he spent nearly twenty years at Siemens in various roles, most recently as the Chief Executive Officer of the Digital Radiology and Medical Informatics business of Siemens Healthcare. His previous roles included President and CEO of the Oncology Care Systems Group, Group Vice President of Siemens e-Health, and Vice President of Siemens Health Services. From 1989 to 1995, he was at Siemens Corporate Research working on Artificial Intelligence, Robotics, Computer Vision, and Image Analysis. During this time, he concurrently served on the faculty at Princeton University.

Dr. Singh has a Ph.D. in Computer Science from Columbia University, a master’s degree in Computer Engineering from Syracuse University, and a bachelor’s degree in Electrical Engineering from Banaras Hindu University, India. He has published two books and numerous refereed articles and holds five patents.

Mark Stevenson, M.B.A.

Former EVP & COO
Thermo Fisher Scientific

Mark Stevenson is an experienced life sciences and diagnostics business leader with over 30 years’ experience commercializing innovations globally.

Mark served as Executive Vice President and Chief Operating Officer at Thermo Fisher Scientific, a company with over $40B in sales and a world leader in serving science through, leading its life science solutions, analytical instruments, specialty diagnostics and laboratory products businesses. He joined Thermo Fisher as Executive Vice President and President of Life Sciences Solutions through the acquisition of Life Technologies. He has also previously served as President and Chief Operating Officer of Life Technologies, and President and Chief Operating Officer of Applied Biosystems prior to its merger with Invitrogen Corporation.

He currently serves on the board of Ingersoll Rand Inc. (NYSE: IR), The Binding Site and the Personalized Medicine Coalition.

Mark holds an M.B.A. from Henley Management School in the U.K., a degree in chemistry from Reading University, U.K.